checkAd
    Startseite > Aktien > Immunome > Nachrichten
    Immunome Aktie
    14,690
     
    USD
    +4,48 %
    +0,630 USD
    Letzter Kurs 02:00:00 Nasdaq
    14,660
     
    USD
    2.200 STK
    Geldkurs 01.05.24
    14,690
     
    USD
    400 STK
    Briefkurs 01.05.24
    ISIN: US45257U1088 · WKN: A2QD9D · SYM: IMNM · USA

    Neueste Nachrichten

    Immunome Appoints Kinney Horn as Chief Business Officer
    14:00 Uhr · Business Wire (engl.) · Immunome
    Immunome Appoints Sandra M. Swain to Board of Directors
    25.04.24 · Business Wire (engl.) · Immunome
    Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
    05.04.24 · Business Wire (engl.) · Immunome
    Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets
    28.03.24 · Business Wire (engl.) · Immunome
    Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
    26.03.24 · Business Wire (engl.) · Immunome
    Immunome to Participate in the Leerink Partners Global Biopharma Conference
    07.03.24 · Business Wire (engl.) · Immunome
    Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference
    01.03.24 · Business Wire (engl.) · Immunome
    Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
    20.02.24 · Business Wire (engl.) · Immunome
    Immunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
    16.02.24 · Business Wire (engl.) · Immunome
    Immunome Announces Pricing of Public Offering of Common Stock
    14.02.24 · Business Wire (engl.) · Immunome
    Immunome Announces Proposed Public Offering of Common Stock
    13.02.24 · Business Wire (engl.) · Immunome
    Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
    06.02.24 · Business Wire (engl.) · Immunome